Anbio Biotechnology (NNNN) stock

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30

$3.82+0.02 (+0.53%)

Close on Nov 13, 2026Market cap $549.66MP/E 26.0Yield –

Anbio Biotechnology gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 87.2%, against 71.9% the year before.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	87.2%	+15.3
FY2024	Dec 31, 2024	71.9%	+21.8
FY2023	Dec 31, 2023	50.1%	−3.3
FY2022	Dec 31, 2022	53.4%	–

Parsed from the XBRL in Anbio Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NNNN.

Revenue growth5.6% · median 2.1%

Gross margin87.2% · median 38.6%

Operating margin66.7% · median -78.9%

Net margin74.1% · median -75.1%

Advertisement
300 × 250

See a number that looks wrong?